Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase 3 study of allogeneic HCT with Iomab-B versus conventional care in older patients with active, relapsed/refractory AML: Pivotal SIERRA trial results
    Meeting Abstract

    Giralt, S.; Gyurkocza, B.; Seropian, S.; Choe, H.; Litzow, M.; Abboud, C.; Koshy, N.; Stiff, P.; Tomlinson, B.; Abhyankar, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • A prospective study of allogeneic stem cell transplantation of A/B T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Tamari, R.; Flynn, J.; Shaffer, B.; Jakubowski, A.; Papadopoulos, E.; Devlin, S.; Lin, R.; Giralt, S.; Perales, M. A.
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • An open-label, single-arm study of letermovir (LTV) for prevention of recurrent CMV infection in highrisk allogeneic hematopoietic cell transplant (HCT) recipients
    Meeting Abstract

    Han, G.; Su, Y.; Stern, A.; Shaffer, B.; Perales, M. A.; Young, J. A.; Papanicolaou, G. A.
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel versus standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma: KarMMa-3, a phase 3 randomized controlled trial
    Meeting Abstract

    Rodríguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
    Meeting Abstract

    El Chaer, F.; Yuda, J.; Mccloskey, J.; Rein, L.; Brown, R.; Green, S.; Pu, J.; Shirane, S.; Shimoda, K.; Ichii, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
    Meeting Abstract

    Quintanal-Villalonga, Á.; Zaidi, S.; Karthaus, W. R.; Zhan, Y. A.; Shafer, M.; Qiu, J.; de Stanchina, E.; Haffner, M. C.; Sawyers, C. L.; Rudin, C. M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
    Meeting Abstract

    Shoushtari, A. N.; Middleton, M. R.; Hamid, O.; Meier, F.; Bauer, T.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
    Meeting Abstract

    Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save